Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Melanoma: HELP
Articles by M. Sabatier-Vincent
Based on 1 article published since 2009
(Why 1 article?)
||||

Between 2009 and 2019, M. Sabatier-Vincent wrote the following article about Melanoma.
 
+ Citations + Abstracts
1 Article [Acantholytic dermatosis in patients treated by vemurafenib: 2 cases]. 2014

Sabatier-Vincent, M / Charles, J / Pinel, N / Challende, I / Claeys, A / Leccia, M-T. ·Clinique de dermatologie et photobiologie, hôpital Nord, CHU de Grenoble, Cs 10217, boulevard de la-Chantourne-La-Tronche, 38043 Grenoble cedex 9, France. Electronic address: msabatiervincent@chu-grenoble.fr. · Clinique de dermatologie et photobiologie, hôpital Nord, CHU de Grenoble, Cs 10217, boulevard de la-Chantourne-La-Tronche, 38043 Grenoble cedex 9, France. · Département d'anatomie pathologique, CHU de Grenoble, Cs 10217, 38043 Grenoble cedex 9, France. ·Ann Dermatol Venereol · Pubmed #25442474.

ABSTRACT: BACKGROUND: Acantholytic dyskeratosis under BRAF inhibitors are dermatological diseases rarely reported to date. PATIENTS AND METHODS: We report 2 cases of acantholytic dyskeratosis, reaching the trunk and the seborrheic zones, not itchy, appeared one month after the introduction of vemurafenib. The histological analysis was typical of a "Grover-like rash" for the 2 patients. DISCUSSION: The appearance of acantholytic dyskeratosis under vemurafenib, a BRAF inhibitor, seems related with a paradoxical activation of the MAP-kinases pathway and with a growth acceleration of lesions in which RAS mutations of keratinocytes. Theses dermatoses seem also to occur with dabrafenib. CONCLUSION: The patients treated by BRAF inhibitors (vemurafenib and dabrafenib) can present acantholytic dyskeratosis. The arisen of this mild dermatosis does not question, of course, the continuation of the treatment. These cutaneous manifestations can be managed with emollients.